Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Optimizing therapy for MRSA pneumonia.

Lee P Skrupky1, Scott T Micek, Marin H Kollef

  • 1Department of Pharmacy, Barnes-Jewish Hospital, 216 S. Kingshighway Boulevard, St. Louis, MO 63110, USA.

Seminars in Respiratory and Critical Care Medicine
|December 21, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predictors of in-hospital mortality among patients with cirrhosis and renal replacement therapy in the ICU: a retrospective cohort study.

Clinics and research in hepatology and gastroenterology·2026
Same author

Dexmedetomidine on supraventricular tachycardia in critical illness: a time-dependent propensity score matching study.

Critical care (London, England)·2026
Same author

Diagnostic Performance of Point-of-Care Immunoassay Measurements of Pancreatic Stone Protein for Sepsis Detection in ICU Patients: A Prospective, Multicenter, Biomarker-Blinded Study.

Critical care medicine·2026
Same author

Optimal antibiotic use in the intensive care unit.

Critical care (London, England)·2025
Same author

EchoLLM: extracting echocardiogram entities with light-weight, open-source large language models.

JAMIA open·2025
Same author

Integrating Nonindividual Patient Features in Machine Learning Models of Hospital-Onset Bacteremia.

JAMA network open·2025
Same journal

Monographic Issue on New Concepts in Acute Exacerbations of COPD.

Seminars in respiratory and critical care medicine·2026
Same journal

Bidirectional Clinical Interactions among Exacerbations and Comorbidities in COPD: A Narrative Review.

Seminars in respiratory and critical care medicine·2026
Same journal

Radiological Approach to Severe Respiratory Infections and Pulmonary Complications in Immunocompromised Patients.

Seminars in respiratory and critical care medicine·2026
Same journal

Two Sides of the Same Smoke: Decoding Respiratory Bronchiolitis-Associated Interstitial Lung Disease and Alveolar Macrophage Pneumonia.

Seminars in respiratory and critical care medicine·2026
Same journal

Role of Vaccination in the Prevention of ECOPD.

Seminars in respiratory and critical care medicine·2026
Same journal

Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Pharmacological Treatment of AECOPD New Perspectives.

Seminars in respiratory and critical care medicine·2026
See all related articles

Methicillin-resistant Staphylococcus aureus (MRSA) causes severe pneumonia. Vancomycin treatment failures are rising, prompting investigation into alternative therapies like linezolid for better MRSA pneumonia outcomes.

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Pharmacology

Background:

  • Staphylococcus aureus is a leading cause of diverse pneumonia types.
  • Increasing methicillin resistance complicates treatment and prevention of MRSA pneumonia.
  • Community-associated MRSA (CA-MRSA) presents unique clinical challenges.

Purpose of the Study:

  • To review the epidemiology of MRSA pneumonia.
  • To discuss current and emerging pharmacotherapies for MRSA pneumonia.
  • To highlight challenges in treating MRSA pneumonia.

Main Methods:

  • Literature review of MRSA pneumonia epidemiology.
  • Analysis of pharmacotherapeutic options for MRSA pneumonia.
  • Examination of factors influencing vancomycin efficacy and failure.

Related Experiment Videos

Main Results:

  • Vancomycin, a first-line agent, faces increasing resistance and therapeutic failures.
  • Factors influencing vancomycin outcomes include isolate genetics, lung penetration, and PK/PD variables.
  • Retrospective data suggest linezolid may outperform vancomycin, pending prospective trials.

Conclusions:

  • MRSA pneumonia treatment is challenging due to rising resistance and vancomycin limitations.
  • Further research and clinical trials are needed to validate alternative therapies.
  • Optimizing pharmacotherapy is crucial for improving MRSA pneumonia patient outcomes.